Mustang Bio's Interim CFO Resigns After 10 Months

Dow Jones11-16 07:55

By Adam L. Cataldo

Mustang Bio's interim Chief Financial Officer James Murphy has resigned after about 10 months in the position, and was replaced on an interim basis by President and Chief Executive Officer Manuel Litchman.

Murphy resigned on Nov. 12, and his departure wasn't the result of a disagreement on any matter relating to the company's operations, policies or practices, Mustang Bio said Friday in a Securities and Exchange Commission filing. He was appointed to the post on Jan. 19.

Earlier this week the company said a Nasdaq Hearings Panel approved its request for an extension to evidence compliance with listing requirement on the Nasdaq Capital Market. That includes the $1 bid price requirement through Jan. 31, and the $2.5 million stockholders' equity requirement, through Feb. 18.

The company's stock closed the session down 3.1% at 23 cents per share. The shares have plunged 83% this year.

Based in Worcester, Mass., Mustang Bio is a clinical-stage biopharmaceutical company focused on translating breakthroughs in cell therapies into potential cures for difficult-to-treat cancers.

Write to Adam Cataldo at adam.cataldo@wsj.com.

(END) Dow Jones Newswires

November 15, 2024 18:55 ET (23:55 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483653050?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-16 07:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2483653050","market":"nz","top_or_hot":-1,"title":"Mustang Bio's Interim CFO Resigns After 10 Months","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Adam L. Cataldo \n</p>\n<p>\n  Mustang Bio's interim Chief Financial Officer James Murphy has resigned after about 10 months in the position, and was replaced on an interim basis by President and Chief Executive Officer Manuel Litchman. \n</p>\n<p>\n  Murphy resigned on Nov. 12, and his departure wasn't the result of a disagreement on any matter relating to the company's operations, policies or practices, Mustang Bio said Friday in a Securities and Exchange Commission filing. He was appointed to the post on Jan. 19. \n</p>\n<p>\n  Earlier this week the company said a Nasdaq Hearings Panel approved its request for an extension to evidence compliance with listing requirement on the Nasdaq Capital Market. That includes the $1 bid price requirement through Jan. 31, and the $2.5 million stockholders' equity requirement, through Feb. 18. \n</p>\n<p>\n  The company's stock closed the session down 3.1% at 23 cents per share. The shares have plunged 83% this year. \n</p>\n<p>\n  Based in Worcester, Mass., Mustang Bio is a clinical-stage biopharmaceutical company focused on translating breakthroughs in cell therapies into potential cures for difficult-to-treat cancers. \n</p>\n<p>\n  Write to Adam Cataldo at adam.cataldo@wsj.com. \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 15, 2024 18:55 ET (23:55 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mustang Bio's Interim CFO Resigns After 10 Months</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMustang Bio's Interim CFO Resigns After 10 Months\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-16 07:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Adam L. Cataldo \n\n\n  Mustang Bio's interim Chief Financial Officer James Murphy has resigned after about 10 months in the position, and was replaced on an interim basis by President and Chief ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FT_SY_NQ","symbol_name":"NQ100指数","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2483653050","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483653050","pubTimestamp":1731714900,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Mustang Bio's interim Chief Financial Officer James Murphy has resigned after about 10 months in the position, and was replaced on an interim basis by President and Chief Executive Officer Manuel Litchman.Murphy resigned on Nov. 12, and his departure wasn't the result of a disagreement on any matter relating to the company's operations, policies or practices, Mustang Bio said Friday in a Securities and Exchange Commission filing. He was appointed to the post on Jan. 19.Earlier this week the company said a Nasdaq Hearings Panel approved its request for an extension to evidence compliance with listing requirement on the Nasdaq Capital Market. That includes the $1 bid price requirement through Jan. 31, and the $2.5 million stockholders' equity requirement, through Feb. 18.The company's stock closed the session down 3.1% at 23 cents per share. The shares have plunged 83% this year.Based in Worcester, Mass., Mustang Bio is a clinical-stage biopharmaceutical company focused on translating br","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","MBIO":"Mustang Bio, Inc"},"translate_title":"野马生物临时首席财务官10个月后辞职","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MBIO":0.9,"NQmain":0.63},"content_text":"By Adam L. Cataldo \n\n\n  Mustang Bio's interim Chief Financial Officer James Murphy has resigned after about 10 months in the position, and was replaced on an interim basis by President and Chief Executive Officer Manuel Litchman. \n\n\n  Murphy resigned on Nov. 12, and his departure wasn't the result of a disagreement on any matter relating to the company's operations, policies or practices, Mustang Bio said Friday in a Securities and Exchange Commission filing. He was appointed to the post on Jan. 19. \n\n\n  Earlier this week the company said a Nasdaq Hearings Panel approved its request for an extension to evidence compliance with listing requirement on the Nasdaq Capital Market. That includes the $1 bid price requirement through Jan. 31, and the $2.5 million stockholders' equity requirement, through Feb. 18. \n\n\n  The company's stock closed the session down 3.1% at 23 cents per share. The shares have plunged 83% this year. \n\n\n  Based in Worcester, Mass., Mustang Bio is a clinical-stage biopharmaceutical company focused on translating breakthroughs in cell therapies into potential cures for difficult-to-treat cancers. \n\n\n  Write to Adam Cataldo at adam.cataldo@wsj.com. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 15, 2024 18:55 ET (23:55 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"Executive Changes","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483653050"}